| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 60 | 2023 | 5432 | 3.820 |
Why?
|
| Lung Neoplasms | 80 | 2024 | 13586 | 3.350 |
Why?
|
| Quinazolines | 25 | 2012 | 1373 | 2.500 |
Why?
|
| Protein Kinase Inhibitors | 36 | 2024 | 5704 | 2.290 |
Why?
|
| Receptor, erbB-3 | 7 | 2021 | 142 | 1.940 |
Why?
|
| Exons | 11 | 2022 | 2394 | 1.770 |
Why?
|
| Antineoplastic Agents | 39 | 2022 | 13677 | 1.610 |
Why?
|
| Mesothelioma | 13 | 2008 | 811 | 1.360 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2021 | 5341 | 1.330 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 14 | 2023 | 1767 | 1.220 |
Why?
|
| Proto-Oncogene Proteins c-met | 9 | 2024 | 564 | 1.200 |
Why?
|
| Pleural Neoplasms | 9 | 2008 | 612 | 1.170 |
Why?
|
| Aniline Compounds | 4 | 2023 | 1094 | 1.090 |
Why?
|
| Mutation | 41 | 2023 | 30237 | 1.010 |
Why?
|
| Receptor, erbB-2 | 7 | 2022 | 2603 | 0.950 |
Why?
|
| Genes, ras | 7 | 2021 | 663 | 0.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2020 | 11878 | 0.800 |
Why?
|
| Mutagenesis, Insertional | 3 | 2022 | 661 | 0.780 |
Why?
|
| Cell Line, Tumor | 38 | 2024 | 17142 | 0.750 |
Why?
|
| Gene Amplification | 6 | 2020 | 1095 | 0.750 |
Why?
|
| Benzeneacetamides | 1 | 2019 | 36 | 0.650 |
Why?
|
| Guanine | 5 | 2008 | 280 | 0.610 |
Why?
|
| Glutamates | 5 | 2008 | 385 | 0.610 |
Why?
|
| Acrylamides | 2 | 2020 | 261 | 0.610 |
Why?
|
| Indoles | 3 | 2021 | 1836 | 0.590 |
Why?
|
| Camptothecin | 1 | 2021 | 600 | 0.590 |
Why?
|
| Oncogenes | 3 | 2021 | 1234 | 0.570 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 719 | 0.520 |
Why?
|
| Pyrimidines | 8 | 2023 | 3048 | 0.510 |
Why?
|
| Adenocarcinoma | 9 | 2016 | 6395 | 0.500 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3670 | 0.490 |
Why?
|
| Thiazoles | 3 | 2019 | 1542 | 0.450 |
Why?
|
| Immunoconjugates | 1 | 2021 | 975 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2020 | 4528 | 0.430 |
Why?
|
| High-Throughput Screening Assays | 2 | 2018 | 942 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3612 | 0.420 |
Why?
|
| Enzyme Inhibitors | 7 | 2023 | 3728 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1801 | 0.370 |
Why?
|
| Maximum Tolerated Dose | 6 | 2021 | 899 | 0.370 |
Why?
|
| ras Proteins | 5 | 2020 | 1058 | 0.370 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2007 | 89 | 0.340 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2012 | 331 | 0.340 |
Why?
|
| Carboplatin | 2 | 2012 | 797 | 0.330 |
Why?
|
| Taxoids | 1 | 2012 | 667 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 6 | 2020 | 1495 | 0.320 |
Why?
|
| Mutation, Missense | 5 | 2023 | 2592 | 0.320 |
Why?
|
| Humans | 123 | 2024 | 768171 | 0.310 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 344 | 0.310 |
Why?
|
| Cisplatin | 5 | 2006 | 1660 | 0.310 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2007 | 17 | 0.300 |
Why?
|
| Benzimidazoles | 2 | 2013 | 864 | 0.300 |
Why?
|
| Sulfones | 3 | 2018 | 448 | 0.300 |
Why?
|
| Apoptosis | 11 | 2021 | 9527 | 0.300 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2007 | 93 | 0.280 |
Why?
|
| Mice | 25 | 2024 | 82049 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2020 | 228 | 0.280 |
Why?
|
| Morpholines | 2 | 2007 | 584 | 0.280 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 6847 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2018 | 2885 | 0.270 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 1613 | 0.270 |
Why?
|
| Pyrazoles | 4 | 2020 | 2028 | 0.270 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 324 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 8648 | 0.260 |
Why?
|
| Quinazolinones | 1 | 2007 | 219 | 0.260 |
Why?
|
| DNA, Neoplasm | 7 | 2018 | 1744 | 0.260 |
Why?
|
| Quinolines | 4 | 2020 | 772 | 0.250 |
Why?
|
| Pyridazines | 2 | 2020 | 203 | 0.250 |
Why?
|
| Point Mutation | 3 | 2024 | 1596 | 0.250 |
Why?
|
| Signal Transduction | 15 | 2019 | 23648 | 0.240 |
Why?
|
| Deoxyribonuclease I | 1 | 2006 | 228 | 0.240 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2018 | 2521 | 0.240 |
Why?
|
| Animals | 32 | 2024 | 169285 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2013 | 2459 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2012 | 1246 | 0.230 |
Why?
|
| Treatment Outcome | 24 | 2021 | 65379 | 0.230 |
Why?
|
| DNA Mutational Analysis | 8 | 2019 | 4120 | 0.220 |
Why?
|
| Benzamides | 5 | 2020 | 1379 | 0.220 |
Why?
|
| Phosphorylation | 11 | 2012 | 8316 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 10763 | 0.220 |
Why?
|
| Survival Analysis | 12 | 2008 | 10099 | 0.210 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 59626 | 0.210 |
Why?
|
| Loss of Heterozygosity | 2 | 2004 | 663 | 0.200 |
Why?
|
| raf Kinases | 2 | 2020 | 117 | 0.200 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 225 | 0.200 |
Why?
|
| Aged | 41 | 2021 | 171502 | 0.200 |
Why?
|
| Middle Aged | 44 | 2021 | 223487 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2020 | 2433 | 0.190 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 18349 | 0.190 |
Why?
|
| Cell Proliferation | 10 | 2020 | 10478 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2013 | 1628 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 6124 | 0.190 |
Why?
|
| Imidazoles | 2 | 2020 | 1169 | 0.190 |
Why?
|
| Female | 52 | 2023 | 397187 | 0.180 |
Why?
|
| NIH 3T3 Cells | 3 | 2019 | 669 | 0.180 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 26 | 0.180 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 2059 | 0.180 |
Why?
|
| ras-GRF1 | 1 | 2020 | 26 | 0.180 |
Why?
|
| Amino Acid Substitution | 4 | 2017 | 1743 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 2846 | 0.170 |
Why?
|
| Drug Synergism | 4 | 2019 | 1760 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 213 | 0.170 |
Why?
|
| Mice, Transgenic | 6 | 2019 | 9561 | 0.170 |
Why?
|
| Acetonitriles | 1 | 2019 | 55 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 204 | 0.160 |
Why?
|
| Male | 48 | 2021 | 364731 | 0.160 |
Why?
|
| Receptors, CXCR | 1 | 2019 | 52 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 9262 | 0.160 |
Why?
|
| Luciferases, Firefly | 1 | 2018 | 37 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2007 | 2909 | 0.160 |
Why?
|
| Pyridines | 4 | 2020 | 2894 | 0.160 |
Why?
|
| Adult | 37 | 2021 | 223646 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 714 | 0.160 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2019 | 196 | 0.160 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1837 | 0.150 |
Why?
|
| Genomics | 8 | 2023 | 5926 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 4913 | 0.150 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 331 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2020 | 2627 | 0.150 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 426 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2019 | 341 | 0.140 |
Why?
|
| Meningeal Neoplasms | 1 | 2006 | 1253 | 0.140 |
Why?
|
| Epidermal Growth Factor | 3 | 2005 | 697 | 0.140 |
Why?
|
| Personality | 1 | 2000 | 559 | 0.140 |
Why?
|
| Disease Progression | 9 | 2017 | 13668 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 2230 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3806 | 0.130 |
Why?
|
| Drug Administration Schedule | 5 | 2008 | 4861 | 0.130 |
Why?
|
| Janus Kinase 2 | 2 | 2018 | 561 | 0.130 |
Why?
|
| Alleles | 2 | 2006 | 6894 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2023 | 2062 | 0.130 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 2048 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 454 | 0.130 |
Why?
|
| Smoking | 2 | 2012 | 9092 | 0.130 |
Why?
|
| Molecular Conformation | 1 | 2017 | 540 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 561 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2007 | 474 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 614 | 0.120 |
Why?
|
| Codon | 1 | 2017 | 599 | 0.120 |
Why?
|
| Membrane Proteins | 3 | 2022 | 7876 | 0.120 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 2211 | 0.120 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 76 | 0.120 |
Why?
|
| Neoplasms | 9 | 2020 | 22371 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
| Piperazines | 2 | 2019 | 2554 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2018 | 1344 | 0.120 |
Why?
|
| Gene Dosage | 3 | 2010 | 1219 | 0.110 |
Why?
|
| Cell Cycle | 4 | 2013 | 2934 | 0.110 |
Why?
|
| Iodine Radioisotopes | 1 | 2018 | 1034 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 1667 | 0.110 |
Why?
|
| Prognosis | 10 | 2023 | 30009 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 342 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 109 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 806 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 16044 | 0.110 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2013 | 24 | 0.110 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 11244 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 757 | 0.110 |
Why?
|
| Immunity | 1 | 2019 | 1003 | 0.110 |
Why?
|
| Clinical Trials as Topic | 6 | 2016 | 8052 | 0.110 |
Why?
|
| Cell Survival | 3 | 2019 | 5789 | 0.100 |
Why?
|
| Internal-External Control | 3 | 2003 | 348 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 2 | 2005 | 419 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1512 | 0.100 |
Why?
|
| RNA Interference | 4 | 2013 | 2832 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2830 | 0.100 |
Why?
|
| ran GTP-Binding Protein | 1 | 2011 | 53 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2019 | 3623 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 500 | 0.100 |
Why?
|
| Receptors, Mitogen | 1 | 2011 | 61 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 2810 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 717 | 0.090 |
Why?
|
| Naphthyridines | 1 | 2013 | 185 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 531 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 733 | 0.090 |
Why?
|
| src-Family Kinases | 2 | 2011 | 539 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 3772 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2013 | 372 | 0.090 |
Why?
|
| Placebos | 2 | 2012 | 1667 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11677 | 0.080 |
Why?
|
| Transfection | 3 | 2006 | 5756 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3590 | 0.080 |
Why?
|
| Sequence Analysis | 1 | 2010 | 240 | 0.080 |
Why?
|
| Genome, Human | 3 | 2016 | 4446 | 0.080 |
Why?
|
| Butadienes | 2 | 2007 | 107 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6975 | 0.080 |
Why?
|
| Combined Modality Therapy | 6 | 2007 | 8542 | 0.080 |
Why?
|
| Genotype | 4 | 2018 | 13045 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 2018 | 2059 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2017 | 5402 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 330 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2013 | 597 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 1996 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 615 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2007 | 714 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2010 | 488 | 0.070 |
Why?
|
| Folic Acid Antagonists | 1 | 2008 | 74 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2010 | 368 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 430 | 0.070 |
Why?
|
| Cell Division | 2 | 2007 | 4477 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2014 | 1683 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2956 | 0.070 |
Why?
|
| CHO Cells | 2 | 2007 | 1379 | 0.070 |
Why?
|
| Protein Binding | 2 | 2017 | 9343 | 0.070 |
Why?
|
| Gene Expression | 2 | 2017 | 7601 | 0.070 |
Why?
|
| Genes, p16 | 1 | 2007 | 159 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2007 | 2661 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2007 | 110 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2006 | 4620 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 9419 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4786 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 2004 | 0.070 |
Why?
|
| Mosaicism | 1 | 2010 | 480 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 11095 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 1535 | 0.070 |
Why?
|
| Cricetinae | 2 | 2007 | 2423 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 725 | 0.060 |
Why?
|
| Stress, Psychological | 2 | 2003 | 4530 | 0.060 |
Why?
|
| Sirolimus | 3 | 2012 | 1540 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 5804 | 0.060 |
Why?
|
| Radiation Pneumonitis | 1 | 2006 | 100 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 371 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2007 | 182 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 1406 | 0.060 |
Why?
|
| Chromones | 1 | 2005 | 148 | 0.060 |
Why?
|
| Survival | 1 | 2005 | 160 | 0.060 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 134 | 0.060 |
Why?
|
| Cricetulus | 1 | 2007 | 812 | 0.060 |
Why?
|
| Doxycycline | 1 | 2007 | 349 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 381 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 466 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2006 | 306 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2006 | 1497 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4648 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 2006 | 114 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2018 | 905 | 0.060 |
Why?
|
| Pleura | 1 | 2006 | 248 | 0.060 |
Why?
|
| Cell Shape | 1 | 2005 | 371 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 2541 | 0.060 |
Why?
|
| Polycythemia Vera | 1 | 2006 | 160 | 0.060 |
Why?
|
| Interleukin-3 | 1 | 2005 | 425 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2006 | 361 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2360 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 646 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2005 | 268 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 6082 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 2931 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 3445 | 0.060 |
Why?
|
| Nitriles | 2 | 2007 | 980 | 0.050 |
Why?
|
| Medical Oncology | 3 | 2011 | 2346 | 0.050 |
Why?
|
| Finland | 1 | 2005 | 609 | 0.050 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 163 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-4F | 1 | 2023 | 41 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2008 | 887 | 0.050 |
Why?
|
| Pneumonectomy | 2 | 2007 | 1156 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39354 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 1062 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2023 | 129 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2007 | 4034 | 0.050 |
Why?
|
| Exanthema | 1 | 2007 | 503 | 0.050 |
Why?
|
| Survival Rate | 2 | 2007 | 12840 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 1305 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2006 | 416 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 22380 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 4168 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9497 | 0.050 |
Why?
|
| Tuberous Sclerosis | 1 | 2010 | 1042 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 785 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 14729 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 681 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1623 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2019 | 54924 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 20762 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2007 | 5028 | 0.050 |
Why?
|
| Diarrhea | 1 | 2007 | 1320 | 0.040 |
Why?
|
| Depression | 1 | 2000 | 8230 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2016 | 3463 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9540 | 0.040 |
Why?
|
| Remission Induction | 1 | 2006 | 2410 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 381 | 0.040 |
Why?
|
| Carcinoma | 1 | 2011 | 2332 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2006 | 798 | 0.040 |
Why?
|
| Terminal Care | 1 | 2011 | 1770 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2020 | 159 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2017 | 1906 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2011 | 1791 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2003 | 779 | 0.040 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 3948 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1230 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1778 | 0.040 |
Why?
|
| Base Sequence | 2 | 2006 | 12422 | 0.040 |
Why?
|
| Cytokines | 1 | 2013 | 7452 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2016 | 1758 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4280 | 0.040 |
Why?
|
| Communication | 2 | 2003 | 3905 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 2631 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1606 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2004 | 2603 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
| Antibodies | 1 | 2005 | 2421 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2007 | 2923 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 297 | 0.040 |
Why?
|
| Patient Selection | 2 | 2007 | 4260 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2732 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 10266 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2237 | 0.030 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2016 | 22 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2020 | 2300 | 0.030 |
Why?
|
| Quality of Life | 2 | 2011 | 13490 | 0.030 |
Why?
|
| Software | 2 | 2016 | 4480 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 829 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 6316 | 0.030 |
Why?
|
| Genome | 1 | 2004 | 1754 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2012 | 1110 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9617 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15453 | 0.030 |
Why?
|
| Young Adult | 5 | 2021 | 60066 | 0.030 |
Why?
|
| Cell Movement | 2 | 2005 | 5213 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2016 | 252 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 209 | 0.030 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 1885 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1864 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1995 | 117 | 0.030 |
Why?
|
| Lung | 2 | 2019 | 10101 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6525 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2018 | 81760 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2006 | 24318 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 963 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2945 | 0.030 |
Why?
|
| Thymine Nucleotides | 1 | 2013 | 57 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 14164 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1105 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 736 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 2012 | 67 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 1995 | 3721 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 651 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1146 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2013 | 1142 | 0.020 |
Why?
|
| Furans | 1 | 2012 | 202 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 1816 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1995 | 733 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 3643 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 200 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2020 | 1982 | 0.020 |
Why?
|
| Health Status | 1 | 2004 | 4091 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 423 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 21207 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2012 | 327 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 3556 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6231 | 0.020 |
Why?
|
| Morphine | 1 | 1995 | 658 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 343 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1436 | 0.020 |
Why?
|
| Social Support | 1 | 2000 | 2193 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 432 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 2568 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 10632 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 18415 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 482 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 311 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5315 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 2663 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 273 | 0.020 |
Why?
|
| Research Design | 1 | 2005 | 6209 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3929 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 271 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 4539 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2862 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2001 | 3269 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 412 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 6669 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 1680 | 0.020 |
Why?
|
| Anthracenes | 1 | 2007 | 83 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2007 | 111 | 0.020 |
Why?
|
| Proteins | 2 | 2012 | 6009 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8741 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1081 | 0.020 |
Why?
|
| Cell Line | 2 | 2013 | 15602 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 1151 | 0.020 |
Why?
|
| Tablets | 1 | 2006 | 149 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 611 | 0.020 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2005 | 46 | 0.020 |
Why?
|
| DNA Replication | 1 | 2013 | 1427 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1995 | 2025 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2005 | 116 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 1120 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 440 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 1995 | 2191 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 1884 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 856 | 0.020 |
Why?
|
| Time Factors | 2 | 2005 | 40220 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 1474 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 6330 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 1730 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 874 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 1351 | 0.010 |
Why?
|
| Physicians | 1 | 2003 | 4598 | 0.010 |
Why?
|
| Hospice Care | 1 | 2011 | 678 | 0.010 |
Why?
|
| Drug Approval | 1 | 2011 | 821 | 0.010 |
Why?
|
| Endonucleases | 1 | 2007 | 371 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 1966 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2009 | 944 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 1995 | 1765 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 693 | 0.010 |
Why?
|
| Radiography | 1 | 2015 | 6986 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2011 | 1188 | 0.010 |
Why?
|
| Educational Status | 1 | 2011 | 2515 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2011 | 2674 | 0.010 |
Why?
|
| Metabolomics | 1 | 2013 | 1674 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 9118 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4887 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3620 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2023 | 12171 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2012 | 4149 | 0.010 |
Why?
|
| DNA Damage | 1 | 2013 | 2469 | 0.010 |
Why?
|
| Research | 1 | 2011 | 1979 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2013 | 3447 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3604 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 1995 | 2913 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2202 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1904 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 5505 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 17623 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2011 | 1256 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 878 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2005 | 354 | 0.010 |
Why?
|
| Role Playing | 1 | 2001 | 21 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2828 | 0.010 |
Why?
|
| United States | 4 | 2016 | 73039 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2010 | 1068 | 0.010 |
Why?
|
| Computational Biology | 1 | 2014 | 3567 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2005 | 663 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 930 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2005 | 565 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 874 | 0.010 |
Why?
|
| Massachusetts | 1 | 2014 | 8890 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8375 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2005 | 1385 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 2916 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1995 | 5919 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4585 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 1418 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 3628 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 1779 | 0.010 |
Why?
|
| Health Policy | 1 | 2011 | 2697 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6229 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 2451 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41753 | 0.010 |
Why?
|
| Feedback | 1 | 2001 | 799 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 1733 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7852 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7609 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 1240 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 3239 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3517 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2007 | 2982 | 0.010 |
Why?
|
| Phenotype | 2 | 2010 | 16726 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 3956 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3415 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2011 | 4754 | 0.010 |
Why?
|
| Child | 2 | 2016 | 80917 | 0.010 |
Why?
|
| Moclobemide | 1 | 1995 | 4 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 2741 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 89169 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 5520 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 7213 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 3474 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 2907 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1995 | 193 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13422 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1995 | 1018 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12077 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4363 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 10397 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 3490 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 15662 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 18065 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 36741 | 0.000 |
Why?
|
| Psychometrics | 1 | 1995 | 3063 | 0.000 |
Why?
|
| Pain Measurement | 1 | 1995 | 3583 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 4793 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1995 | 12466 | 0.000 |
Why?
|
| Anxiety | 1 | 1995 | 4672 | 0.000 |
Why?
|